Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Ilaprazole not inferior to rabeprazole in treatment of duodenal ulcer

06 Oct 2019

The efficacy of ilaprazole 5 mg appears to be on a par with rabeprazole 10 mg in treating duodenal ulcer, a study has shown. In addition, there is a dose-effect relationship between 5- and 10-mg ilaprazole.

In this double-blind, parallel, randomized study, patients aged >18 years with at least one endoscopically confirmed active nonmalignant duodenal ulcer received either rabeprazole 10 mg or ilaprazole 5/10 mg for 4 weeks. Ulcer healing was characterized by resolution from active to scarring stage.

The investigators assessed symptoms relief using a graded score and evaluated the safety and tolerability of these study drugs based on clinical assessments.

In total, 390 patients completed the study. Duodenal ulcer was successfully healed in 75.38 percent of patients in the rabeprazole 10-mg group, 77.86 percent in the ilaprazole 5-mg group and 83.72 percent in the ilaprazole 10-mg group after 4 weeks of treatment.

The 4-week healing rate difference between rabeprazole 10 mg and ilaprazole 5 mg was 2.58 percent (95 percent CI, –7.79 percent to 12.74 percent), showing the noninferiority of the latter. In logistic regression analysis, ilaprazole 10 mg was superior to ilaprazole 5 mg at week 2 (odds ratio, 1.92, 1.02–3.59; p=0.04).

Eighty percent of patients became asymptomatic after treatment. All three drug groups showed comparable efficacy and safety profile at the dosages administered.

“Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.